Document is current
Any future updates will be listed below
-
Authors
Haspeslagh, Eline
van Helden, Mary J
Deswarte, Kim
De Prijck, Sofie
van Moorleghem, Justine
Boon, Louis
Hammad, Hamida
Vivier, Eric
Lambrecht, Bart N https://orcid.org/0000-0003-4376-6834
-
Funding
Funding for this research was provided by:
Lung Foundation Netherlands (3.2.11.090FE)
FWO Excellence of Science (G0G2318N)
Innate‐Pharma
MSDAvenir
La Ligue Nationale contre le Cancer
Flanders Research Foundation (FWO13/ASP/138)
European Research Council (41D04510W)
Ghent University (GOA 01G02817)
Agence Nationale de la Recherche
- License Information
-
More Information
Article History
Received: 6 November 2017
Revised: 12 January 2018
Accepted: 18 January 2018
First Online: 15 February 2018
Conflict of interest
: Disclosure of potential conflict of interest: Prof. Dr. Eric Vivier is co‐founder, scientific advisor, and shareholder of Innate‐Pharma. The other authors declare that they have no conflict of interest.
